Consumer Health Care Products Industry Earnings Roundup
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Likes Consumer, But Not U.S. Tax Policy; Consumer Segment Stays At Reckitt, Rx To Leave; Merck Consumer Brands Strong With Division Sale Pending; Exchange Rates Deflate Bayer Growth; No Buyer’s Remorse At Sanofi; and Gummy Vitamin Business Soars For C&D
You may also be interested in...
RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health
RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.
RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health
RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.
RB Consumer Provides Bright Spot In Dim Quarter Despite Slower Sales
RB missed analysts third-quarter expectations by 1%, reporting a 2% sales increase to $3.82 billion. Consumer health product sales led the way with a 6% increase to $1.21 billion, dragged down slightly by slower than expected uptake of Mucinex and MegaRed products.